Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26533082 | 1.00 | LMNA (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL27084374 | 0.91 | KRAS (0.33) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL27084377 | 0.91 | KRAS (0.33) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL26533212 | 0.91 | THRB (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL30776563 | 0.91 | THRB (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL26533081 | 0.90 | LMNA (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL30776381 | 0.90 | LMNA (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL26532869 | 0.88 | LMNA (0.34) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL30776371 | 0.88 | LMNA (0.34) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL30776322 | 0.88 | EIF4EBP1 (0.35) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3550/4885POLB 1641/4885MEN1 226/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | LMNA 3550/4885POLB 1641/4885MEN1 226/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3550/4885POLB 1641/4885MEN1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.